We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Nanoparticles Deliver Viral Gene That Activates Toxic Drug Inside Brain Cancer Cells

By LabMedica International staff writers
Posted on 17 Feb 2015
Print article
Image: Nanoparticles in low and high resolution micrographs (Photo courtesy of Green Laboratory, Johns Hopkins University).
Image: Nanoparticles in low and high resolution micrographs (Photo courtesy of Green Laboratory, Johns Hopkins University).
Cancer researchers have described a nanoparticle-based gene therapy system that inserted the gene for the enzyme herpes simplex virus type I thymidine kinase (HSVtk) into brain tumor (glioma) cells and rendered them highly sensitive to the chemotherapeutic agent ganciclovir.

Ganciclovir is a synthetic analogue of 2′-deoxy-guanosine. It is first phosphorylated to ganciclovir monophosphate by a viral kinase during infection. Subsequently, cellular kinases catalyze the formation of ganciclovir diphosphate and ganciclovir triphosphate, which is present in 10-fold greater concentrations in Cytomegalovirus (CMV) or herpes simplex virus (HSV)-infected cells than uninfected cells. Ganciclovir triphosphate is a competitive inhibitor of deoxyguanosine triphosphate (dGTP) incorporation into DNA and preferentially inhibits viral DNA polymerases more than cellular DNA polymerases. In addition, ganciclovir triphosphate serves as a poor substrate for chain elongation, thereby disrupting viral DNA synthesis by a second route. Use of ganciclovir for cancer treatment is restricted by a range of serious side effects. Common adverse drug reactions include: granulocytopenia, neutropenia, anemia, thrombocytopenia, fever, nausea, vomiting, dyspepsia, diarrhea, abdominal pain, raised liver enzymes, headache, confusion, hallucination, seizures, pain and phlebitis at injection site (due to high pH), sweating, rash, itch, increased serum creatinine and blood urea concentrations. Furthermore, ganciclovir is considered a potential human carcinogen, teratogen, and mutagen.

Investigators at Johns Hopkins University (Baltimore, MD, USA) devised a way to use a less toxic pro-drug form of ganciclovir (GCV) that would become activated by HSVtk enzyme action localized inside the cancer cells. To transport the HSVtk gene to tumor cells they fabricated nanoparticles from HSVtk DNA combined with the poly(beta-amino ester) (PBAE) polymer, poly(1,4-butanediol diacrylate-co-4-amino-1-butanol) end-modified with 1-(3-aminopropyl)-4-methylpiperazine. The nanoparticles were 138 ± 4 nanometers in size and 13 ± 1 millivolts in zeta potential.

Results published in the February 2, 2015, online edition of the journal ACS Nano revealed that the HSVtk DNA-containing nanoparticles showed 100% cancer cell killing in vitro in two glioma cell lines when combined with GCV exposure, while control nanoparticles encoding an irrelevant gene maintained robust cell viability.

For in vivo evaluation, tumor-bearing rats were treated with PBAE/HSVtk infusion via convection-enhanced delivery (CED) in combination with systemic administration of GCV. Intracranial CED employed a pressure gradient to enhance diffusion throughout the tumor. Following a single CED infusion, labeled PBAE nanoparticles spread completely throughout the tumor, and the treated animals showed a significant benefit in survival.

"We evaluated the system in rats with glioma and found that by using a method called intracranial convection-enhanced delivery, our nanoparticles could penetrate completely throughout the tumor following a single injection," said senior author Dr. Jordan J. Green, associate professor of biomedical engineering and ophthalmology at Johns Hopkins University. "When combined with systemic administration of ganciclovir, rats with malignant glioma lived significantly longer than rats that did not receive this treatment. We will move forward by evaluating this technology in additional brain cancer animal models."

Related Links:

Johns Hopkins University


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.